La 1,25-dihydroxyvitamine D et son récepteur

Revue du Rhumatisme (Edition Francaise)

Volumn 67, Issue SUPPL.2, 2000, Pages 39-45

  Garabédian, Michèle ^a  

^a HÔPITAL SAINT VINCENT DE PAUL   (France)

Author keywords

1,25 dihydroxyvitamin D; Bone metabolism; Calcium metabolism; Vitamin D receptor

Indexed keywords

EID: 10444251170     PISSN: 11698330     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1169-8330(00)80076-9     Document Type: Article

References (39)

1. Fraser DR. Regulation of the metabolism of vitamin D. Physiol Rev 1980; 60: 551-613.
2. Kawashima H, Kurokawa K. Metabolism and sites of action of vitamin D in the kidney. Kidney Int 1986 ; 29 : 98-107.
3. Fu GK, Lin D, Zhang MY, Bikle DD, Shackleton CH, Miller WL, et al. Cloning of human 25-hydroxyvitamin D-1-alpha-hydroxylase and mutations causing vitamin D-dependent rickets type I. Mol Endocrinol 1997 ; 11 : 1961-70.
4. 2-vitamin D3 in healthy adults. J Clin Endocrinol Metab 1978 ; 46 : 756-66.
5. Portale A, Halloran B, Morris RC, Jr. Physiologic regulation of the serum concentration of 1,25-dihydroxyvitamin D by phosphorus in normal men. J Clin Invest 1989 ; 83 : 1494-9.
6. Dawson-Hugues B, Harris S, Dallai GE. Serum ionised calcium, as well as phosphorus and parathyroid hormone, is associated with the plasma 1,25-dihydroxyvitamin D3 concentration in normal post-menopausal women. J Bone Miner Res 1991 ; 6 : 461-8.
7. Ho SC, MacDonald D, Chan C, Fan YK, Chan SSG, Swaminathan R. Determinants of serum 1,25-dihydroxyvitamin D concentration in healthy premenopausal subjects. Clin Chim Acta 1994 ; 230 : 21-33.
8. Menaa C, Vrtovsnik F, Friedlander G, Corvol M, Garabédian M. Insulin-like growth factor I, a unique calcium-dependent stimulator of 1,25-dihydroxyvitamin D3 production. J Biol Chem 1995 ; 270 : 25461-7.
9. van Hoof HJC, van der Mooren MJ, Swinkels LMJW, Rolland R, Benraad TJ. Hormone replacement therapy increases serum 1,25-dihydroxyvitamin D: a 2-year prospective study. Calcif Tissue Int 1994 ; 55 : 417-9.
10. Hahn TJ, Halstead LR, Baran DT. Effects of short term glucocorticoid administration on intestinal calcium absorption and circulating vitamin D metabolite concentration in man. J Clin Endocrinol Metab 1981 ; 52 : 111-5.
11. Glass AR, Eil C. Ketoconazole-induced reduction in sérum 1,25-dihydroxyvitamin D and total serum calcium in hypercalcemic patients. J Clin Endocrinol Metab 1988 ; 66 : 934-8.
12. Dusso A, Finch J, Delmez J, Rapp N, Lopez-Hilker S, Brown A, et al. Extrarenal production of calcitriol. Kidney Int 1990 ; 38 : S36-S40.
13. Kumar R, Cohen WR, Silva P, Epstein FH. Elevated 1,25-dihydroxyvitamin D plasma levels in normal pregnancy and lactation. J Clin Invest 1979 ; 63 : 342-5.
14. 2D3 production by T lymphocyte and alveolar macrophages recovered by lavage from normocalcemic patients with tuberculosis. J Clin Invest 1990 ; 85 : 1588-93.
15. Davies M, Hayes ME, Yin JAL, Berry JL, Mawer ER. Abnormal synthesis of 1,25-dihydroxyvitamin D in patients with malignant lymphoma. J Clin Endocrinol Metab 1994 ; 78 : 1202-7.
16. 2D3. J Cell Physiol 1994 ; 159 : 131-41.
17. Schwartz Z, Brooks B, Swain L, Del Toro F, Norman A, Boyan B. Production of 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 by growth zone and resting zone chondrocytes is dependent on cell maturation and is regulated by hormones and growth factors. Endocrinology 1992 ; 130 : 2495-2504.
18. Garabédian M, Menn S, Nguyen TM, Ruiz JC, Callens A, Uhlrich J. Prévention de la carence en vitamine D chez l'enfant et l'adolescent. I. Proposition pour l'utilisation d'un abaque décisionnel. Arch Pédiatr 1999 ; 6 : 990-1000.
19. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocrine Rev 1995 ; 16 : 200-257.
20. Ohyama Y, Ozono K, Uchida M, Shinki T, Kato S, Suda T, et al. Identification of a vitamin D-responsive element in the 5'-flanking region of the rat 25-hydroxyvitamin D3 24-hydroxylase gene. J Biol Chem 1994 ; 269 : 10545-50.
21. St-Arnaud R, Glorieux FH. 24,25-Dihydroxyvitamin D-active metabolite or inactive catabolite? Endocrinology 1998 ;139 : 3371-4.
22. Balsan S, Garabédian M, Larchet M, Gorski AM, Cournot G, Tau C, et al. Long-term nocturnal calcium infusions can cure rickets and promote normal mineralization in hereditary resistance to 1,25-dihydroxyvitamin D. J Clin Invest 1986 ; 77 : 1661-7.
23. Yoshizawa T, Handa Y, Uematsu Y, Takeda S, Sekine K, Yoshihara Y, et al. Mice lacking the vitamin D receptor exhibit impaired bone formation, uterine hypoplasia and growth retardation after weaning. Nat Genet 1997 ; 16 : 391-6.
24. Malloy PJ, Pike JW, Feldman D. The vitamin D receptor and the syndrome of hereditary 1,25-dihydroxyvitamin D-resistant rickets. Endocrine Rev. 1999 ; 20 : 156-88.
25. Kumar R. The metabolism and mechanism of action of 1,25-dihydroxyvitamin D3. Kidney Int 1986 ; 30 : 93-103.
26. Nemere I, Schwartz Z, Pedrozo H, Sylvia VL, Dean DD, Boyan BD. Identification of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J Bone Miner Res 1998 ; 13 : 1353-9.
27. SudaT, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997 ; 12 : 869-79.
28. Friedman PA, Gesek FA. Cellular calcium transport in renal epithelia: measurement, mechanisms, regulation. Physiol Rev 1995 ; 75 : 429-71.
29. Silver J, Naveh-Many T, Mayer H, Schmelzer HJ, Popovtzer MM. Regulation by vitamin D metabolites of parathyroid hormone gene transcription in the rat. J Clin Invest 1986 ; 78 : 1296-1301.
30. Yasuda H, Shima N, Nakagawa N, Mochizuki SI, Yano K, Fujise N, et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 1998 ; 139 :1329-37.
31. Johnson JA, Grande JP, Roche PC, Kumar R. Ontogeny of the 1,25-dihydroxyvitamin D3 receptor in fetal rat bone. J Bone Miner Res 1996; 11 : 56-61.
32. Finkelman RD, Linkhart TA, Mohan S, Lau KHW, Baylink DJ, Bell NH. Vitamin D deficiency causes a selective reduction in deposition of transforming growth factor β in rat bone: possible mechanism for impaired osteoinduction. Proc Natl Acad Sci USA 1991 ; 88 : 3657-60.
33. Boland R. Role of vitamin D in skeletal muscle function. Endocr Rev 1986 ; 7 : 434-48.
34. Manolagas SC, Hustmyer FG, Yu XP. Immunomodulating properties of 1,25-dihydroxyvitamin D3. Kidney Int 1990 ; 38 Suppl 29 : S9-S16.
35. Mathieu C, Waer M, Casteels K, Laureys J, Bouillon R. Prevention of type I diabetes in NOD mice by nonhypercalcemic doses of a new structural analog of 1,25-dihydroxyvitamin D3, KH1060. Endocrinology 1995 ; 136 : 866-72.
36. Blutt SE, Weigel NL. Vitamin D and prostate cancer. Proc Soc Exp Biol Med 1999 ;221 : 89-98.
37. Lundin AC, Soderkvist P, Eriksson B, Bergman-Jungestrom M, Wingren S. Association of breast cancer progression with a vitamin D receptor gene polymorphism. South East Sweden Breast Cancer Group. Cancer Res 1999 ; 15 : 2332-4.
38. Haussler MR, Whitfield GK, Haussler CA, Hsieh PD, Thompson SH, Selznik CE, et al. The nuclear vitamin D receptor: biological and molecular regulatoryproperties revealed. Review. J Bone Miner Res 1998 ; 13 : 325-49.
39. 2D3 : past, present, and future. J Bone Miner Res 1998 ; 13 : 1360-9.